1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Semaglutide
Trade Name:
Rybelsus
Manufacturer/Distributor:
Novo Nordisk Canada Inc.
Classification:
Incretin mimetic
ATC Class:
A10BJ06 - semaglutide
Status:
active
Notice of Compliance (yyyy/mm/dd):
2020/03/30
Date Marketed in Canada (yyyy/mm/dd):
2020/04/19
Presentation:
Tablet: 3 mg. DIN: 02497581
Tablet: 7 mg. DIN: 02497603
Tablet: 14 mg. DIN: 02497611
Comments:
Oral therapy as adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Previous forms of semaglutide have been for parenteral administration.
Back to:
Drug Product Listings 
